Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rakesh Kapoor has a total of 228 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ConLymphNet: A Generalizable Region-Constrained Deep Learning Architecture for Precise Abdominal Lymph Node Segmentation Across Cancer Types.

    by Pankaj Gupta, Shubham Saini, Anjali Aggarwal, Ajay Gulati, Shraddha Patkar, Niharika Dutta, Sakshi Jeswani, Lovleen Kakkar, Kartik Bose, Gaurav Prakash, et al.

    Accurate identification and segmentation of abdominal lymph nodes on computed tomography (CT) is crucial for cancer staging and treatment planning but remains a challenging and time-consuming radiologic task. We developed and validated ConLymphNet, a deep learning-based approach for automated abdominal lymph node segmentation using vertebral landmarks as anatomic reference points to standardize the region of interest. We implemented a novel preprocessing pipeline incorporating vertebral landmark-based region selection followed by a 3D nnUNet segmentation model. The model was trained on 481 contrast-enhanced CT scans from patients with gallbladder cancer (GBC) and validated on external data sets including GBC (n = 54), public lymph node (n = 81), and multicancer data sets (n = 606). Performance was compared with three radiologists of varying experience levels. Interobserver agreement among radiologists and the incremental value of artificial intelligence (AI)-assisted reading were also assessed. To support reproducibility and future research, we also contribute 45 expert-verified lymph node segmentations for cases from public multicancer data sets. ConLymphNet achieved mean Dice coefficients of 0.696 ± 0.179, 0.631 ± 0.187, and 0.639 ± 0.176 and low false-positive rates of 0.78 ± 0.35, 0.81 ± 0.33, 0.93 ± 0.47/volume on internal cross-validation, external GBC, and public lymph node data sets, respectively. Performance varied by lymph node location (P = .0080) and size (P = .0444), with larger nodes yielding better results. The model's detection rate (89.6%) was comparable with experienced residents (89.2%) but with reduced processing time (28.7 ± 12.4s v 165.3 ± 47.8 s). AI assistance improved radiologists' performance significantly, particularly for less experienced readers (detection rate +20.2%, segmentation accuracy +13.0%, P < .001), while reducing false positives by 33.3%. ConLymphNet demonstrates reasonable performance across diverse cancer types and imaging protocols, offering segmentation accuracy comparable with radiologists with substantially faster processing times.

  • Efficacy and safety of peptide receptor radionuclide therapy in advanced foregut and hindgut neuroendocrine tumors: a real-world experience from a single institution

    by Piyush Aggarwal, Ashwani Sood, Divya Khosla, Rakesh Kapoor, Gaurav Prakash, Divya Dahiya, Sanjay Kumar Bhadada, Rama Walia, Rajesh Gupta, Bhagwant Rai Mittal

    Foregut and hindgut neuroendocrine tumors (NETs) contribute significantly to the global NET burden especially in Asian population; however, these cohorts are sparse and underrepresented in current trials assessing peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic (GEP) NETs. This single-centre study evaluates the efficacy and safety of PRRT in advanced foregut and hindgut NETs. Retrospective data evaluation of consecutive patients with biopsy-proven metastatic foregut (gastric, lung and thymic NETs) and hindgut NETs (colorectal, anal and sacral NETs) who underwent PRRT from 2014 to 2024 at a tertiary care hospital was done. Up to four cycles of 177Lu-DOTATATE (7.4 GBq/cycle) were administered intravenously every 6-8 weeks along with nephroprotection. Interim and end-of-treatment 68Ga-DOTANOC PET/CT scans were acquired for response evaluation, based on RECIST v1.1. Objective response rate (ORR), disease control rate (DCR), best biochemical response, toxicity profile, quality-of-life scores, progression-free survival (PFS) and overall survival (OS) were assessed. Thirty-four patients (median age-56 yrs) with foregut (n = 16) and hindgut (n = 18) NETs received a total of 111 cycles (range 1-4) of 177Lu-DOTATATE (median cumulative activity 26.5 GBq). The best ORR and DCR were 45% and 80%, median PFS was 29.7 months (95% CI, 20.3-39.1), and the 1- and 5-year OS rates were 93.8% (95% CI, 85.4-100) & 53.6% (95% CI, 28.6-78.6), respectively, after a median follow-up of 45.3 months. Grade 3 adverse events were observed in only five patients. PRRT appears to be safe and effective treatment modality in advanced foregut and hindgut NETs. More prospective trials are required to validate these findings in larger cohorts.

  • CT-based multimodal prediction model for chemotherapy response in gallbladder cancer: integration of imaging and clinical biomarkers—a prospective pilot study

    by Kritika Sharma, Pankaj Gupta, Ajay Gulati, Niharika Dutta, Divya Khosla, Gaurav Prakash, Thakur Yadav, Lileswar Kaman, Santosh Irrinki, Harjeet Singh, et al.

    Background Gallbladder carcinoma (GBC) is an aggressive malignancy with poor prognosis, often diagnosed at advanced stages. While chemotherapy forms the cornerstone of treatment for locally advanced and metastatic disease, reliable predictors of response remain elusive. This exploratory pilot study aimed to develop a computed tomography (CT)-based prediction model incorporating clinical and biochemical parameters to identify patients likely to respond to chemotherapy. Methods This prospective study enrolled consecutive treatment-naïve patients with cytologically/histologically proven locally advanced or metastatic GBC scheduled for chemotherapy between July 2023 and March 2025. All patients underwent biphasic contrast-enhanced CT within 14 days prior to chemotherapy initiation. Demographic variables, biochemical parameters, and tumor markers (CA 19 − 9, CEA) were systematically recorded. CT-based response assessment was performed using RECIST 1.1 criteria after two cycles of chemotherapy. Three exploratory prediction models were developed using logistic regression with appropriate variable selection methods and penalized regression to address small sample size. Results Of 25 patients (18 females, mean age 50.0 ± 11.6), 11 (44%) achieved partial response while 14 (56%) were non-responders (stable or progressive disease). Univariate analysis identified calculus presence (p = 0.002), largest liver metastasis size (p = 0.001), ascites (p = 0.008), age (p = 0.128), ALT (p = 0.241), and CEA levels (p = 0.123) as potential predictors. After correction for optimism using bootstrap validation, the CT-only model achieved area under the receiver operating characteristic curve (AUC) of 0.82 (95% CI: 0.64–0.92) with 80.0% accuracy, 92.3% sensitivity, and 62.5% specificity (Nagelkerke R²=0.272). The clinical-only model yielded optimism-corrected AUC of 0.74 (95% CI: 0.51–0.88) with 68.0% accuracy, 71.4% sensitivity, and 63.6% specificity (Nagelkerke R²=0.424). The combined model showed better performance with optimism-corrected AUC of 0.85 (95% CI: 0.67–0.95), 84.0% accuracy, 85.7% sensitivity, 81.8% specificity, and highest explained variance (Nagelkerke R²=0.662). Gallstone presence emerged as a potential predictor associated with treatment response across models, while larger liver lesions and elevated CEA showed trends that may be associated with poor response. Conclusions This preliminary hypothesis-generating study suggests that integration of baseline CT imaging features with clinical parameters may potentially allow prediction of chemotherapy response in GBC patients. The identified factors require external validation in larger multi-institutional cohorts before clinical implementation can be considered.

  • Radiological signature of HER2-Positive gallbladder cancer: analysis of CT features

    by Pankaj Gupta, Niharika Dutta, Shravya Singh, Nikita Pradhan, Ruby Siddiqui, Ajay Gulati, Naveen Kalra, Gaurav Prakash, Thakur Yadav, Lileswar Kaman, et al.

    Objective This study aimed to identify distinctive computed tomography (CT) features associated with human epidermal growth factor receptor 2 (HER2) status in gallbladder cancer (GBC) that could serve as noninvasive imaging biomarkers. Materials and methods This study included 213 patients with pathologically confirmed GBCs with availability of HER2 status (171 HER2-negative, 42 HER2-positive). Pre-treatment contrast-enhanced CT scans were evaluated by two radiologists blinded to HER2 status. Multivariate analysis was performed using logistic regression with L2 regularization. Model discrimination was assessed using receiver operating characteristic (ROC) analysis, and internal validation was performed using bootstrap resampling (1,000 iterations) to correct for optimism. Results HER2-positive tumors exhibited larger lymph nodes (1.93 ± 0.79 cm vs. 1.61 ± 0.61 cm, p = 0.015), less frequent gallstones (14.3% vs. 35.7%, p = 0.013), arterial phase hyperenhancement (20.0% vs. 44.1%, p = 0.026), mass-like morphology (35.7% vs. 55.6%, p = 0.033), and more frequent biliary compression by lymph nodes (19.0% vs. 4.1%, p = 0.002). Multivariate analysis identified biliary compression by lymph nodes as the strongest positive predictor of HER2 positivity [odds ratio (OR) 2.99, 95% CI: 1.25–7.04], while arterial phase hyperenhancement (OR 0.40, 95% CI: 0.19–0.75), gallstone presence (OR 0.40, 95% CI: 0.18–0.75), and mass-like morphology (OR 0.54, 95% CI: 0.29–0.95) were significant negative predictors. The model demonstrated good discrimination (area under the ROC curve 0.782) with sensitivity 75%, specificity 79.4%, and negative predictive value 96.2%. Conclusion HER2-positive GBCs display characteristic CT findings that can be utilized for noninvasive diagnosis with robust predictive performance.


  • Open Access

    Bridging hope: Retrospective analysis of stereotactic radiotherapy in patients with hepatocellular carcinoma-A promising and cost-effective solution for low-and middle-income countries

    by Rakesh Kapoor, Treshita Dey, Divya Khosla, Sunil Taneja, Naveen Kalra, Rajesh Gupta

    Background: Hepatocellular carcinoma (HCC) is one of the most common cancers among men in India. Stereotactic body radiation therapy (SBRT) has recently become a promising treatment modality for HCC before liver transplantation. Objectives: In this retrospective study, we aimed primarily to determine the clinical details of patients with HCC and response of SBRT in treating such patients with a secondary objective of assessing the impact of SBRT on patient survival. Materials and Methods: This retrospective analysis was conducted from January 2016 to January 2019 at the Department of Radiotherapy at Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Six MV photons were used in conjunction with volumetric modulated arc treatment to deliver SBRT. Tumor response was evaluated as per the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. For both overall survival (OS) and progression-free survival (PFS), Kaplan–Meier curves were created. Results: We included 21 patients with HCC who received SBRT treatment. The median age of our patients was 63 (45–74) years. The radiation dose ranged from 36–50 Gy in 3–5 fractions. Of the 21 patients, 5 (23.8%) had a complete response, whereas 9 (42.9%) showed a partial response. After 2 years, the local control rate was 66.7%. The overall survival was 28 months (interquartile range, IQR, 22–37), and the median progression-free survival was 20 months (IQR, 16–27). The overall survival rate at 2 years was 59%. There was no treatment-related mortality observed and no patient required an urgent transplant for acute decompensation. Conclusion: SBRT was well tolerated by our patients. With advancements in external beam radiotherapy (EBRT) techniques, it is possible to practice higher dose fractionation regimens due to more precise targeting and sparing of normal liver tissue. Considering the long waiting period for liver transplantation, liver SBRT can prove to be a successful bridging tool.

  • Open Access

    Chemotherapy related changes in cfDNA levels in squamous non-small cell lung cancer: correlation with symptom scores and radiological responses

    by Nithiyanandan Ravi, Parul Gupta, Amanjit Bal, Kuruswamy Thurai Prasad, Mandeep Garg, Rakesh Kapoor, Navneet Singh

    Aim: There is limited data on prognostic value of baseline plasma cell free DNA (cfDNA) in advanced squamous non-small cell lung cancer (sq-NSCLC). This prospective observational study aimed to assess change in plasma cfDNA levels in locally-advanced/metastatic sq-NSCLC with chemotherapy and its correlation with symptom-scores and radiological-responses. Methods: Chemotherapy-naive patients with stages-IIIB/IIIC/IV sq-NSCLC (n = 59), smokers with chronic obstructive pulmonary disease [COPD, COPD-controls (CC); n = 27] and healthy-controls (n = 25) were enrolled. Respiratory symptom burden (RSB) and total symptom burden (TSB) were calculated from mean visual-analog-scores (VAS) of dyspnoea, cough, chest pain, hemoptysis RSB, anorexia and fatigue (all six for TSB). cfDNA was isolated from peripheral blood. All patients received platinum-doublet chemotherapy. RSB/TSB/cfDNA assessment and contrast-enhanced computed tomography (CECT)-thorax scans were done at baseline and post-chemotherapy. Results: At baseline, 13/59 (22%) sq-NSCLC, 3/27 (11%) CC and none (0%) healthy-controls had detectable cfDNA. All three CC were heavy smokers with no evidence of malignancy and undetectable cfDNA levels on repeat testing. In sq-NSCLC group, majority were males (95%), current-smokers (88%), heavy-smokers (70%), had metastatic disease (59%) with median age of 65 years. Eastern Co-operative Oncology Group (ECOG) performance status (PS) was 0–1 (56%) and 2 (42%). Median RSB- and TSB-scores were 9 [interquartile range (IQR) = 5–14] and 16 (IQR = 9–23), respectively. Of the 59 patients, 54 received ≥ 1 cycle while 27 underwent post-C4 evaluation with detectable cfDNA levels in 18/27 (66.7%). No baseline characteristic correlated with cfDNA detectability. Median overall survival (OS) and progression-free survival (PFS) were 262 days and 167 days, respectively. ECOG PS ≥ 2, RSB-score > 9 and TSB-score > 16 were all associated with worse OS and PFS as was cfDNA detectability [median OS = 97 days vs. 298 days and median PFS = 97 days vs. 197 days; P = 0.025; hazard ratio (HR) = 2.17]. Conclusions: Baseline cfDNA detectability is independently associated with poor OS and PFS in patients with advanced sq-NSCLC on chemotherapy.


  • Open Access

    Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches

    by Divya Khosla, Shagun Misra, Pek Lim Chu, Peiyong Guan, Ritambhra Nada, Rajesh Gupta, Khwanta Kaewnarin, Tun Kiat Ko, Hong Lee Heng, Vijay Kumar Srinivasalu, et al.

    Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting FGFR2 gene fusions and IDH1 mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy.


  • Simultaneous Integrated Boost (SIB) Versus Sequential Boost in Anal Cancer Patients: A Single-Center Experience

    by Divya Khosla, Rakesh Kapoor, Treshita Dey, Vaishali Kataria, Ranjit Singh, Divyesh Kumar, Arun Singh Oinam, Rajesh Gupta, Surinder Singh Rana, Jimil Shah, et al.

    Purpose Concurrent chemoradiation is the standard of care for the treatment of anal cancer. Radiation can be delivered by sequential or simultaneous integrated boost (SIB) approach. The present study was conducted to compare the treatment outcomes and toxicity profile of patients with anal cancer treated with sequential boost and SIB approach. Methods A single-institution retrospective analysis of patients with squamous cell carcinoma of the anal canal treated between 2019 and 2022 with radical chemoradiation was performed. The sequential boost schedule consisted of 45 Gy in 25 fractions (1.8 Gy daily) to the gross tumor, nodes, and elective nodal volume, followed by a 9 Gy in five fractions boost to the gross disease. Patients receiving SIB were treated as per RTOG 0529 protocol. In both the groups, patients were treated with volumetric modulated arc therapy (VMAT). The two groups were compared in terms of overall survival (OS), colostomy-free survival (CFS), relapse-free survival (RFS), and acute toxicity profile. p-values < 0.05 were considered statistically significant. Results The patient and disease characteristics in both treatment arms were comparable. The only difference was a significantly longer overall treatment time of ≥ 50 days in the sequential arm (77.8% vs 43.8%, p = 0.04). The median follow-up was 18 months. The 2-year CFS was 80% in sequential vs 87.5% at 2 years for the SIB arm, 2-year OS 83.3% vs 58.6%, and 2-year RFS was 38.9% vs 41.7%, respectively. A total of 14 (77.8%) in sequential and 8 (50%) in the SIB arm had disease relapse. On univariate analysis, the involved pelvic lymph node significantly affected OS (HR 10.45, p = 0.03) while inguinal lymph node involvement adversely affected RFS (HR 6.16, p = 0.02). The most common acute toxicity was radiation-induced dermatitis, 15 (83.4%; 5 grade II, 10 grade III) in sequential vs 7 (43.8%; 3 each grade II and III) in the SIB group followed by hematological (61.1% vs 68.75%). However, the incidence of overall acute toxicities was significantly less in the SIB arm (p = 0.006). Conclusion Our study showed that concurrent chemoradiation with the SIB-VMAT approach is well tolerated in patients of anal carcinoma and resulted in lesser treatment interruptions and comparable outcomes as compared to the sequential approach. Our results warrant further evaluation in a prospective study.